Lite Strategy Inc (LITS)
NASDAQ:LITS
Want to see LITS full AI Analyst Report?
Top Page
Lite Strategy
(NASDAQ:LITS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$1.00
▼(-24.81% Downside)
Action:Reiterated
Date:05/15/26
The score is primarily held down by weak financial performance, driven by zero revenue in recent periods, large losses, and ongoing cash burn despite a debt-free balance sheet. Technicals are slightly positive in the near term but still lag the long-term trend, and valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A zero-debt position with positive equity provides durable financial flexibility: lower fixed obligations reduce bankruptcy risk and give management runway to fund operations or R&D from equity resources, improving capacity to execute strategy without immediate refinancing.
Negative Factors
Zero revenue in recent periods
A complete absence of reported revenue is a durable structural concern: without recurring sales, the firm cannot cover fixed costs or validate market demand. This undermines margins, growth prospects, and makes recovery dependent on restarting commercial activity or new product launches.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt position with positive equity provides durable financial flexibility: lower fixed obligations reduce bankruptcy risk and give management runway to fund operations or R&D from equity resources, improving capacity to execute strategy without immediate refinancing.
Read all positive factors
Lite Strategy (LITS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.26M
Dividend YieldN/A
Average Volume (3M)291.64K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue GrowthN/A
EPS Growth57.61%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryAsset Management - Cryptocurrency
Share Statistics
EPS (TTM)-9.13
Shares Outstanding34,025,200
10 Day Avg. Volume456,948
30 Day Avg. Volume291,641
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.78
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lite Strategy Business Overview & Revenue Model
Company Description
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, In...
Lite Strategy Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
48
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 65.30M | 48.82M | 40.70M | 34.80M |
| Gross Profit | 0.00 | -368.00K | 65.30M | 48.82M | 40.70M | 33.39M |
| EBITDA | -12.10M | -17.09M | 25.82M | -36.38M | -75.16M | -41.02M |
| Net Income | -60.82M | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
Balance Sheet | ||||||
| Total Assets | 57.79M | 18.29M | 41.38M | 120.81M | 177.84M | 174.10M |
| Cash, Cash Equivalents and Short-Term Investments | 7.54M | 18.01M | 38.34M | 100.69M | 153.25M | 153.43M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.73M | 9.64M | 8.30M |
| Total Liabilities | 952.00K | 1.35M | 8.36M | 96.19M | 125.43M | 124.63M |
| Stockholders Equity | 56.84M | 16.93M | 33.02M | 24.62M | 52.41M | 49.47M |
Cash Flow | ||||||
| Free Cash Flow | -10.42M | -20.84M | -50.48M | -52.52M | -49.23M | -32.67M |
| Operating Cash Flow | -10.42M | -20.84M | -50.47M | -52.48M | -48.75M | -31.96M |
| Investing Cash Flow | -97.33M | 35.15M | 49.14M | 53.69M | 6.89M | 24.71M |
| Financing Cash Flow | 94.82M | 0.00 | -11.87M | -40.00K | 49.05M | 3.47M |
Lite Strategy Technical Analysis
Negative
1.33
Price Trends
1.16
Negative
1.21
Negative
1.99
Negative
Market Momentum
>-0.01
Positive
41.17
Neutral
18.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 1.17, above the 50-day MA of 1.16, and below the 200-day MA of 1.99, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.17 is Neutral, neither overbought nor oversold. The STOCH value of 18.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.
Lite Strategy Risk Analysis
Lite Strategy disclosed 29 risk factors in its most recent earnings report. Lite Strategy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lite Strategy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $273.43M | -6.79 | -118.24% | ― | 138.86% | 42.14% | |
47 Neutral | $69.10M | -3.65 | -201.43% | ― | ― | 33.86% | |
46 Neutral | $37.26M | -0.08 | -90.81% | ― | ― | 57.61% | |
45 Neutral | $22.58M | -0.05 | -191.12% | ― | ― | 38.53% | |
43 Neutral | $27.22M | -47.59 | -88.89% | ― | -100.00% | -170.04% |
* Healthcare Sector Average
LITS
Lite Strategy
1.12
-1.03
-47.91%
ABVC
ABVC BioPharma
1.10
-0.09
-7.56%
JSPR
Jasper Therapeutics
0.87
-3.95
-81.91%
PRLD
Prelude Therapeutics
4.50
3.59
394.51%
GANX
Gain Therapeutics
1.65
-0.16
-8.84%
ESLA
Estrella Immunopharma
1.14
0.13
12.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.